AdvisorShares ETF Hails Trump Order to Fast-Track Psilocybin, MDMA, Ibogaine Therapies
President Trump’s April 18 executive order directs federal agencies to fast-track review of ibogaine, psilocybin and MDMA therapies for PTSD, TBI, depression and addiction. AdvisorShares portfolio manager Dan Ahrens says the action validates clinical breakthroughs and strengthens the investment case for the Psychedelics ETF’s exposure to this emerging sector.
1. Executive Order Accelerates Psychedelic Therapies
On April 18, President Trump signed an executive order directing federal agencies to expedite review and expand access to psychedelic-assisted treatments, including ibogaine, psilocybin and MDMA, targeting mental health disorders such as PTSD, traumatic brain injury, depression and addiction.
2. ETF Manager Highlights Investment Opportunity
Dan Ahrens, managing director at AdvisorShares and portfolio manager of the Psychedelics ETF, calls the order a historic signal that elevates psychedelic medicine from peripheral research to national priority and strengthens the case for dedicated ETF exposure to companies developing these therapies.
3. Sector Outlook and Clinical Evidence
PTSD affects an estimated 29.5 million Americans and veterans face elevated suicide rates, while over 414,000 service members have TBI diagnoses since 2000. Recent peer-reviewed research reports dramatic reductions in PTSD symptoms and suicidal ideation among special operations veterans treated with ibogaine, suggesting regulatory support could unlock significant market growth.